PLATFORM Study of Precision Medicine for Rare Tumors

Phase 2 Recruiting 770 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Phase II, open label, non-randomized, multiple-arm, single-center clinical trial in patients with advanced rare solid tumors who failed to standard treatment.

Timeline

Start: 2020-08-15
Primary completion: 2026-07-01
Completion: 2028-07-01

Publications

Wang S, Huang HY, Wu D, Fang H, Ying J, Bai Y, Yu Y, Fang Y, Jiang N, Sun C, Yu A, Fan Q, Xing S, Ni Y, Zhang W, Wu C, Ji X, Wang H, Guo Y, Tang Q, Wang Y, Tang Y, Li N. Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours. BMJ Open. 2021 Jun 3;11(6):e044543. doi: 10.1136/bmjopen-2020-044543.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alectinib	Small molecule	600 mg	Oral
Subject	Almonertinib	Small molecule	110 mg	Oral
Subject	Atezolizumab	Monoclonal antibody	1200 mg	Intravenous
Subject	Atezolizumab	Monoclonal antibody	1680 mg	Intravenous
Subject	Crizotinib	Small molecule	250 mg	Oral
Subject	DACOMITINIB ANHYDROUS	Small molecule	45 mg	Oral
Subject	Imatinib	Small molecule	400 mg	Oral
Subject	Niraparib	Small molecule	200 mg	Oral
Subject	Niraparib	Small molecule	300 mg	Oral
Subject	Palbociclib	Small molecule	125 mg	Oral
Subject	Pyrotinib	Small molecule	400 mg	Oral
Subject	Sintilimab	Monoclonal antibody	200 mg	Intravenous
Subject	Vemurafenib	Small molecule	960 mg	Oral

Indications

No indication recorded.